Investigating how mitochondrial protein translation affects cell survival
Mitoribosome protein translation signaling and survival mechanisms
This study is looking at how problems with tiny parts of our cells called mitochondria can cause cell damage, especially when we're under stress, and it's testing certain antibiotics to see if they can help protect our cells from this damage, which could lead to new treatments for mitochondrial diseases and issues related to aging.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11126750 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of mitochondrial function in cell survival, particularly under stress conditions. It explores how mitochondrial dysfunction, which can occur due to genetic mutations or aging, leads to cellular damage and death. The study employs high-throughput screening of antibiotics, specifically tetracyclines, to identify compounds that can protect cells from damage by targeting the mitoribosome protein translation. By examining these mechanisms, the research aims to uncover potential therapeutic strategies for mitochondrial diseases and age-related conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with mitochondrial diseases, neurodegenerative conditions, or age-related impairments.
Not a fit: Patients with non-mitochondrial related diseases or those without any mitochondrial dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve cell survival in patients with mitochondrial diseases and age-related disorders.
How similar studies have performed: Previous research has shown promise in using antibiotics like tetracyclines to target mitochondrial dysfunction, indicating a potential for success in this approach.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Puigserver, Pere — Dana-Farber Cancer Inst
- Study coordinator: Puigserver, Pere
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.